Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6
In the retatrutide trials, a dose range of 1 to 12 mg per week subcutaneously was studied
The results showed a significant improvement in skin lesions and a marked reduction in pruritus in most participants who received the active blend
related full-length recombinant thymosin beta-4 (a different formulation than the marketed TB-500 fragment) has also been examined in small human studies for cardiac and dermatologic indications Examined in preclinical models, including diabetic rat Achilles tendon and rat ligament-injury studies, for actin-binding, cell-migration, and angiogenic activity that researchers have proposed as a mechanism for tendon and ligament repair, though this literature remains comparatively sparse for musculoskeletal applications specifically Known risks and side effects: Because TB-500 is manufactured and sold without FDA oversight as a "research chemical," independent testing and industry reporting describe wide variability in purity (with some products measured well below labeled potency) and contamination with heavy metals or bacterial byproducts, unlike pharmaceutical-grade recombinant thymosin beta-4 used in registered clinical trials Thymosin beta-4's core mechanisms, angiogenesis and cell migration, are also pathways exploited by tumors
Retrieved 28 August 2020
US$ 27.36
US$ 20.00
US$ 23.06
US$ 26.63
US$ 27.38
US$ 28.91
US$ 24.21
US$ 23.22
US$ 28.00
